Drug intelligence / Profile preview

Anaprazole

Development stage: Phase 3
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Anaprazole is a proton pump inhibitor (PPI) under development for the treatment of acid-related gastrointestinal disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. Like other PPIs, it works by selectively and irreversibly inhibiting the H+/K+-ATPase enzyme system (the gastric proton pump) in parietal cells of the stomach, thereby reducing gastric acid secretion. Anaprazole is structurally related to other PPIs such as omeprazole and lansoprazole. It has been investigated primarily in East Asia for its efficacy and safety profile compared to existing PPIs.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Anaprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anaprazole.

Explore the full profile